Zinc supplementation has no effect on lipoprotein metabolism, hemostasis, and putative indices of copper status in healthy men.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

The resulting copper deficiency can impact directly upon cholesterol metabolism and a suboptimal copper status has been observed to influence markers of hemostasis (specifically fibrinogen and the copper-containing coagulation factors V and VIII).

A second group took placebo supplements for the full duration of the trial.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, men only.

Thirty-eight subjects were recruited onto a double-blind placebo-controlled intervention trial and randomly selected to one of two groups.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

PubMed files the paper under topics including Copper, Dietary Supplements, Feeding Behavior, Health, Hemostasis, Lipoproteins and No-Observed-Adverse-Effect Level.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Copper (Supplement).

The publication is from 2003 (Biological trace element research), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Copper (Supplement) compound page, all human trials.